CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞介导脑病后的短暂性左心室功能障碍：一种应激性心肌病
英文原题：Transient left ventricular dysfunction following chimeric antigen receptor T-cell-mediated encephalopathy: A form of stress cardiomyopathy.
查看英文原题
Transient left ventricular dysfunction following chimeric antigen receptor T-cell-mediated encephalopathy: A form of stress cardiomyopathy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是治疗淋巴系统恶性肿瘤（如复发/难治性弥漫性大B细胞淋巴瘤，DLBCL）的新策略。CAR-T 治疗已与细胞因子释放综合征（CRS）、神经毒性及心血管毒性等多种毒性相关。CAR-T 治疗后曾报告短暂左心室收缩功能受损，但其机制尚不清楚。本文报告两例复发/难治性DLBCL患者接受CAR-T 后出现脑病和CRS，继而发生符合应激性心肌病表现的短暂左心室功能障碍，并介绍其临床表现和结局。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy represents a new strategy in treating lymphoid malignancies, such as relapsed-refractory diffuse large B-cell lymphoma (DLBCL). Several toxicities including cytokine release syndrome (CRS), neurotoxicity, and cardiovascular toxicity have been linked to CAR T-cell therapy.
Transient impairment in left ventricular systolic function is described after CAR-T, however, the mechanism remains poorly understood. This paper reports the clinical presentation and outcome of two patients with relapsed-refractory DLBCL who experienced encephalopathy and CRS following CAR T-cell therapy and developed transient left ventricular dysfunction consistent with stress cardiomyopathy.
论文信息
- 作者
- Khorasanchi A、Ansari AM、Bottinor W、Simmons G、Abbate A、Toor AA
- 单位
- Department of Internal Medicine Massey Cancer Center, Virginia Commonwealth University Richmond Virginia USA.United States
- 文献类型
- 病例报告
- 期刊
- EJHaem2022 Feb
- 原文标识
- PubMed 35846197 · DOI 10.1002/jha2.369
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →